Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:DNLI NASDAQ:FATE NASDAQ:HALO NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.63-5.1%$1.38$0.87▼$6.78$164.08M0.74836,289 shs58,924 shsDNLIDenali Therapeutics$14.93-2.7%$14.29$10.57▼$33.33$2.18B1.331.13 million shs295,367 shsFATEFate Therapeutics$1.15-1.3%$1.20$0.66▼$5.92$131.22M2.182.22 million shs332,671 shsHALOHalozyme Therapeutics$57.00-1.1%$55.11$42.01▼$70.51$7.02B1.151.75 million shs252,535 shsRVMDRevolution Medicines$38.19-0.8%$39.28$29.17▼$62.40$7.13B1.061.67 million shs241,631 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+4.24%+16.61%+8.18%+81.05%-65.74%DNLIDenali Therapeutics+2.33%+4.46%+0.59%+20.87%-29.10%FATEFate Therapeutics+0.87%+1.31%-30.54%+9.43%-62.82%HALOHalozyme Therapeutics+1.86%+6.62%+7.18%-4.30%+8.82%RVMDRevolution Medicines-0.05%+4.05%-8.29%+7.78%-9.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector4.1099 of 5 stars3.13.00.04.52.62.50.0DNLIDenali Therapeutics4.722 of 5 stars4.52.00.04.73.82.50.0FATEFate Therapeutics4.1992 of 5 stars3.13.00.04.72.61.70.6HALOHalozyme Therapeutics4.615 of 5 stars2.11.00.04.42.72.54.4RVMDRevolution Medicines4.5678 of 5 stars4.52.00.04.73.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00144.95% UpsideDNLIDenali Therapeutics 3.06Buy$33.71125.82% UpsideFATEFate Therapeutics 2.13Hold$3.83234.79% UpsideHALOHalozyme Therapeutics 2.17Hold$62.509.66% UpsideRVMDRevolution Medicines 3.00Buy$68.0078.08% UpsideCurrent Analyst Ratings BreakdownLatest ALEC, DNLI, FATE, RVMD, and HALO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025HALOHalozyme TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$55.006/25/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/24/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.00 ➝ $73.006/24/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.006/12/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/29/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.005/19/2025DNLIDenali TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $27.005/14/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $72.005/14/2025FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.005/14/2025FATEFate TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.005/14/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M1.62N/AN/A$1.29 per share1.27DNLIDenali Therapeutics$330.53M6.56N/AN/A$8.53 per share1.75FATEFate Therapeutics$13.63M9.63N/AN/A$2.80 per share0.41HALOHalozyme Therapeutics$1.02B6.92$4.69 per share12.16$2.86 per share19.93RVMDRevolution Medicines$11.58M614.24N/AN/A$13.47 per share2.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.67N/AN/AN/AN/A-35.90%-32.41%7/30/2025 (Estimated)FATEFate Therapeutics-$186.26M-$1.49N/AN/AN/A-1,318.93%-47.17%-34.60%8/12/2025 (Estimated)HALOHalozyme Therapeutics$444.09M$3.7615.169.160.3844.76%136.91%26.05%8/5/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.00N/AN/AN/AN/A-37.06%-32.84%8/6/2025 (Estimated)Latest ALEC, DNLI, FATE, RVMD, and HALO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DNLIDenali Therapeutics-$0.73N/AN/AN/AN/AN/A8/6/2025Q2 2025ALECAlector-$0.45N/AN/AN/A$2.76 millionN/A8/6/2025Q2 2025RVMDRevolution Medicines-$1.14N/AN/AN/A$0.50 millionN/A8/5/2025Q2 2025HALOHalozyme Therapeutics$1.22N/AN/AN/A$282.66 millionN/A5/13/2025Q1 2025FATEFate Therapeutics-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/A5/6/2025Q1 2025DNLIDenali Therapeutics-$0.71-$0.78-$0.07-$0.78$3.24 millionN/A5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98$1.11+$0.13$0.93$231.21 million$264.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.103.343.34DNLIDenali TherapeuticsN/A9.569.56FATEFate TherapeuticsN/A8.818.81HALOHalozyme Therapeutics3.138.397.30RVMDRevolution MedicinesN/A13.4613.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%DNLIDenali Therapeutics92.92%FATEFate Therapeutics97.54%HALOHalozyme Therapeutics97.79%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipALECAlector9.10%DNLIDenali Therapeutics12.50%FATEFate Therapeutics5.51%HALOHalozyme Therapeutics2.40%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million90.89 millionOptionableDNLIDenali Therapeutics430145.28 million127.12 millionOptionableFATEFate Therapeutics550114.60 million108.29 millionOptionableHALOHalozyme Therapeutics390123.22 million120.26 millionOptionableRVMDRevolution Medicines250186.27 million170.99 millionOptionableALEC, DNLI, FATE, RVMD, and HALO HeadlinesRecent News About These CompaniesRevolution Medicines and Iambic Announce Technology and Research ...3 hours ago | nasdaq.comRevolution Medicines and Iambic Therapeutics Announce ... - Nasdaq3 hours ago | nasdaq.comIambic and Revolution Medicines Partner on AI Cancer Drug DiscoveryJuly 9 at 11:36 PM | genengnews.comGRevolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug CandidatesJuly 9 at 6:35 PM | finance.yahoo.comRevolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug CandidatesJuly 9 at 8:00 AM | globenewswire.comAllspring Global Investments Holdings LLC Trims Position in Revolution Medicines, Inc. (NASDAQ:RVMD)July 9 at 3:32 AM | marketbeat.comChina Universal Asset Management Co. Ltd. Acquires 27,982 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)July 8 at 6:52 AM | marketbeat.comRevolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid TumorsJuly 6, 2025 | msn.comLeerink Partnrs Issues Positive Estimate for RVMD EarningsJuly 4, 2025 | americanbankingnews.comRevolution Medicines, Inc. (NASDAQ:RVMD) Position Boosted by WCM Investment Management LLCJuly 3, 2025 | marketbeat.comRevolution Medicines and Summit Therapeutics Announce Clinical Collaboration to Evaluate RAS (ON) Inhibitors in Combination with Ivonescimab for Solid Tumors - NasdaqJuly 2, 2025 | nasdaq.comLeerink Partnrs Issues Optimistic Estimate for RVMD EarningsJuly 2, 2025 | marketbeat.comRevolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant TumorsJune 30, 2025 | globenewswire.comLunate Capital Ltd Invests $77.66 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)June 29, 2025 | marketbeat.comQ3 EPS Estimate for Revolution Medicines Raised by AnalystJune 27, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Buy" by AnalystsJune 26, 2025 | marketbeat.comRevolution Medicines' (RVMD) Buy Rating Reiterated at GuggenheimJune 25, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for Revolution Medicines (NASDAQ:RVMD)June 24, 2025 | marketbeat.comRevolution Medicines' Daraxonrasib Receives FDA Breakthrough Therapy Designation for Metastatic Pancreatic Ductal Adenocarcinoma | NasdaqJune 24, 2025 | nasdaq.comNeedham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)June 24, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Shares Gap Down - Here's What HappenedJune 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALEC, DNLI, FATE, RVMD, and HALO Company DescriptionsAlector NASDAQ:ALEC$1.63 -0.09 (-5.06%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Denali Therapeutics NASDAQ:DNLI$14.93 -0.42 (-2.74%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Fate Therapeutics NASDAQ:FATE$1.14 -0.02 (-1.29%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Halozyme Therapeutics NASDAQ:HALO$57.00 -0.64 (-1.10%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Revolution Medicines NASDAQ:RVMD$38.19 -0.31 (-0.82%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
